All news articles for June 2022

© GettyImages/acilo

Kite secures third approved cell therapy indication in Europe

By Jane Byrne

The European Commission (EC) has approved Kite’s CAR T-cell therapy, Yescarta, (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.

Pic:getty/hailshadow

Pfizer invests $95m in Valneva

By Rachel Arthur

Pfizer will invest €90.5m ($95m) in French vaccine specialist Valneva, representing 8.1% of Valneva’s share capital. The investment will support the duo’s Lyme disease vaccine partnership.

Pharma industry slams WTO move on TRIPS waiver

Pharma industry slams WTO move on TRIPS waiver

By Jane Byrne

Pharma industry organizations say they are deeply disappointed by the decision taken by World Trade Organization (WTO) at its ministerial conference, MC12, to endorse a TRIPS waiver for COVID-19 vaccines.

Pic:getty/uschools

DIA gears up for Global Annual Meeting

By Rachel Arthur

DIA, the professional global community for healthcare product development, will host its in-person Global Annual Meeting in Chicago on June 19-23.

Pic:getty/oatawa

CureVac acquires Frame Cancer Therapeutics

By Rachel Arthur

CureVac has acquired Frame Cancer Therapeutics: with the German mRNA specialist planning to draw on Frame’s expertise in antigen identification and validation as it develops mRNA cancer vaccines.

Pic:getty/manjurul

GSK gets FDA approval for MMR vaccine Priorix

By Rachel Arthur

The US Food and Drug Administration (FDA) has approved GSK’s Priorix (Measles, Mumps and Rubella Vaccine, Live) for individuals 12 months of age and older.

Pic:getty/cristianstortografia

Monkeypox: The vaccine landscape

By Rachel Arthur

Interest in vaccines against monkeypox is growing as the outbreak spreads around the world. The arsenal includes existing smallpox vaccines and potential new monkeypox specific mRNA vaccines.